5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%

被引：0
|
作者：
Gadgeel, S. [1 ]
Rodriguez-Abreu, D. [2 ]
Halmos, B. [3 ]
Garassino, M. C. [4 ,5 ]
Kurata, T. [6 ]
Cheng, Y. [7 ]
Jensen, E. [8 ]
Shamoun, M. [8 ]
Rajagopalan, K. [8 ]
Paz-Ares, L. [9 ,10 ]
机构：
[1] Henry Ford Hlth, Dept Internal Med, Henry Ford Canc Inst, Detroit, MI USA
[2] Univ Los Palmas de Gran Canaria, CHU Insular Materno Infant Gran Canaria, Las Palmas Gran Canaria, Spain
[3] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY USA
[4] Univ Chicago Med & Biol Sci, Thorac Oncol Program, Chicago, IL USA
[5] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[6] Kansai Med Univ Hosp, Dept Thorac Oncol, Osaka, Japan
[7] Jilin Canc Hosp, Dept Oncol, Changchun, Jilin, Peoples R China
[8] Merck Co Inc, Rahway, NJ USA
[9] Univ Complutense Madrid, Univ 12 Octubre, H12OCNIO Lung Canc Unit, Madrid, Spain
[10] Ciberonc, Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
pembrolizumab; NSCLC; PD-L1-negative;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA14.05
引用
收藏
页码：S77 / S78
页数：2
相关论文
共 50 条
  • [31] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
    Reck, M.
    Rodr-Guez-Abreu, D.
    Robinson, A. G.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M.
    Rao, S.
    Hotta, K.
    Leiby, M.
    Lubiniecki, G. M.
    Shentu, Y.
    Rangwala, R.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
    Reck, M.
    Rodriguez-Abreu, D.
    Robinson, A.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M. E.
    Rao, S.
    Hotta, K.
    Leiby, M.
    Lubiniecki, G.
    Shentu, Y.
    Rangwala, R.
    Brahmer, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [33] Association of PD-L1 tumor proportion score=20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC
    Hamakawa, Yusuke
    Agemi, Yoko
    Shiba, Aya
    Ikeda, Toshiki
    Higashi, Yuko
    Aga, Masaharu
    Miyazaki, Kazuhito
    Taniguchi, Yuri
    Misumi, Yuki
    Nakamura, Yukiko
    Shimokawa, Tsuneo
    Saigusa, Yusuke
    Kobayashi, Nobuaki
    Okamoto, Hiroaki
    Kaneko, Takeshi
    CANCER MEDICINE, 2023, 12 (17): : 17788 - 17797
  • [34] Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score.
    Galsky, Matt D.
    Bajorin, Dean F.
    Witjes, J. Alfred
    Gschwend, Juergen E.
    Tomita, Yoshihiko
    Nasroulah, Federico
    Li, Jun
    Collette, Sandra
    Perez-Valderrama, Begona
    Grimm, Marc-Oliver
    Appleman, Leonard Joseph
    Gravis, Gwenaelle
    Necchi, Andrea
    Ye, Dingwei
    Stenner, Frank
    Wind-Rotolo, Megan
    Zhang, Joshua
    Unsal-Kacmaz, Keziban
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [35] A Matching-Adjusted Indirect Comparison of Pembrolizumab plus Chemotherapy vs. Nivolumab plus Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Insinga, Ralph
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    CANCERS, 2020, 12 (12) : 1 - 15
  • [36] An indirect Comparison of Pembrolizumab plus Chemo vs Ipilimumab plus Nivolumab as First-Line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC
    Halmos, B.
    Burke, T.
    Kalyvas, C.
    Insinga, R.
    Vandormael, K.
    Frederickson, A.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S23
  • [37] Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
    Chen, Ya
    Wang, Yanan
    Yang, Zhengyu
    Hu, Minjuan
    Zhang, Yanwei
    Qian, Fangfei
    Zhang, Wei
    Zhang, Bo
    Han, Baohui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] Durvalumab (D) ± Tremelimumab (T) plus Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
    Garon, E. B.
    Cho, B. C.
    Luft, A.
    Alatorre-Alexander, J.
    Geater, S. L.
    Kim, S. -W.
    Ursol, G.
    Hussein, M.
    Lim, F. L.
    Yang, C. -T.
    Araujo, L. H.
    Saito, H.
    Reinmuth, N.
    Kohlmann, M.
    Shi, X.
    Mann, H.
    Peters, S.
    Mok, T.
    Johnson, M. L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S349 - S350
  • [39] Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up
    Gadgeel, Shirish M.
    Rodriguez-Abreu, Delvys
    Halmos, Balazs
    Garassino, Marina C.
    Kurata, Takayasu
    Cheng, Ying
    Jensen, Erin
    Shamoun, Mark
    Rajagopalan, Kumar
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (08) : 1228 - 1241
  • [40] Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
    She, Longjiang
    Hu, Huabin
    Liao, Mengting
    Xia, Xuefeng
    Shi, Yin
    Yao, Linli
    Ding, Dong
    Zhu, Youwen
    Zeng, Shan
    Shen, Liangfang
    Huang, Jin
    Carbone, David P.
    LUNG CANCER, 2019, 138 : 88 - 94
12345